CLASSICAL TRANSPLANTATION TOLERANCE IN THE ADULT - THE INTERACTION BETWEEN MYELOABLATION AND IMMUNOSUPPRESSION

被引:55
作者
LEONG, LYW [1 ]
QIN, SX [1 ]
COBBOLD, SP [1 ]
WALDMANN, H [1 ]
机构
[1] UNIV CAMBRIDGE, DEPT PATHOL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND
关键词
D O I
10.1002/eji.1830221111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Allogeneic bone marrow transplantation in the neonate is an effective way of inducing permanent tolerance to donor tissue. To do the same in the immunocompetent adult requires immunosuppression to counter host-versus-graft alloreactivity. Conditioning with monoclonal antibodies (mAb) to CD4 and CD8 has been sufficient where donor and recipient are mismatched at only multiple "minor" histocompatibility loci, or at major histocompatibility complex (MHC) class I plus "minor" loci, but not where the mismatch involves the entire MHC. Tolerance across the MHC barrier requires extra conditioning with agents that happen to be both immunosuppressive and myeloablative, so obscuring the assessment of which effect is important. By using dimethylmyleran as a selective "space"-creating myeloablative agent, and CD4 plus CD8 mAb as sole immunosuppressive agents, we have been able to dissect the relative requirements for immunosuppression and myeloablation. We show here that transplantation tolerance could only be achieved when both types of agent were combined together so as to guarantee sufficient donor-type hemopoietic chimerism. We argue that the donor marrow, given sufficient space, will engraft and provide a sustained source of tolerogen overriding any host resistance that antibodies cannot control.
引用
收藏
页码:2825 / 2830
页数:6
相关论文
共 29 条
[1]  
AUCHINCLOSS H, 1988, TRANSPLANT P, V20, P1190
[2]   THE INFLUENCE OF 1,4-DIMETHYLSULFONOXY-1,4-DIMETHYLBUTANE (CB-2348, DIMETHYL MYLERAN) IN NEOPLASTIC DISEASE [J].
BIERMAN, HR ;
KELLY, KH ;
KNUDSON, AG ;
MAEKAWA, T ;
TIMMIS, GM .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1958, 68 (03) :1211-1222
[3]   ACTIVELY ACQUIRED TOLERANCE OF FOREIGN CELLS [J].
BILLINGHAM, RE ;
BRENT, L ;
MEDAWAR, PB .
NATURE, 1953, 172 (4379) :603-606
[4]  
CHAMPLIN RE, 1984, SEMIN HEMATOL, V21, P101
[5]   THERAPY WITH MONOCLONAL-ANTIBODIES BY ELIMINATION OF T-CELL SUBSETS INVIVO [J].
COBBOLD, SP ;
JAYASURIYA, A ;
NASH, A ;
PROSPERO, TD ;
WALDMANN, H .
NATURE, 1984, 312 (5994) :548-551
[6]   MONOCLONAL-ANTIBODIES TO PROMOTE MARROW ENGRAFTMENT AND TISSUE GRAFT TOLERANCE [J].
COBBOLD, SP ;
MARTIN, G ;
QIN, S ;
WALDMANN, H .
NATURE, 1986, 323 (6084) :164-166
[7]   BONE-MARROW TRANSPLANTATION AFTER ANTILYMPHOCYTIC SERUM AND LETHAL CHEMOTHERAPY [J].
FLORSHEI.GL ;
RUSZKIEW.M .
NATURE, 1969, 222 (5196) :854-&
[8]  
KIRSCHNER RH, 1971, CANCER-AM CANCER SOC, V27, P1074, DOI 10.1002/1097-0142(197105)27:5<1074::AID-CNCR2820270511>3.0.CO
[9]  
2-G
[10]   COMPARISON OF ALLOGENEIC AND XENOGENEIC DETERMINANTS ON THE H-2KK MOLECULE [J].
KOCH, S ;
KOCH, N ;
ROBINSON, P ;
HAMMERLING, G .
TRANSPLANTATION, 1983, 36 (02) :177-180